Solventum Corporation $SOLV Position Boosted by Swiss National Bank

Swiss National Bank lifted its holdings in Solventum Corporation (NYSE:SOLV) by 7.4% during the 1st quarter, HoldingsChannel.com reports. The firm owned 458,209 shares of the company’s stock after acquiring an additional 31,600 shares during the quarter. Swiss National Bank’s holdings in Solventum were worth $29,921,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. United Services Automobile Association bought a new stake in Solventum during the first quarter worth approximately $239,000. Woodline Partners LP increased its holdings in shares of Solventum by 40.7% in the first quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock valued at $888,000 after buying an additional 3,377 shares in the last quarter. Intech Investment Management LLC lifted its position in shares of Solventum by 167.0% during the 1st quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock valued at $1,268,000 after acquiring an additional 10,425 shares during the last quarter. First Trust Advisors LP lifted its position in shares of Solventum by 5.8% during the 2nd quarter. First Trust Advisors LP now owns 257,727 shares of the company’s stock valued at $19,546,000 after acquiring an additional 14,151 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Solventum during the 2nd quarter worth $766,000.

Solventum Stock Down 0.4%

Solventum stock opened at $77.29 on Friday. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $88.20. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. The firm has a market cap of $13.39 billion, a PE ratio of 9.47, a P/E/G ratio of 1.20 and a beta of 0.66. The firm’s 50 day moving average price is $77.39 and its two-hundred day moving average price is $74.20.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The business had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same period in the previous year, the company posted $1.34 EPS. Solventum’s revenue was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, research analysts predict that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on SOLV shares. Weiss Ratings upgraded Solventum from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, July 17th. UBS Group cut Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research note on Thursday, May 14th. BTIG Research reaffirmed a “buy” rating and set a $91.00 price objective on shares of Solventum in a research note on Monday, July 13th. Stifel Nicolaus decreased their target price on shares of Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Finally, Piper Sandler dropped their target price on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $81.91.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.